Key Quantitative Figures
The Board approved a proposal to raise funds up to ₹50 crores.
Dates of Action
The Board meeting was held on 26th June, 2026. The meeting commenced at 4:00 PM and concluded at 6:00 PM.
Parties Involved
The Board of Directors of Bacil Pharma Limited. The Managing Director, Chief Financial Officer, Company Secretary and other officials were authorized to execute fund-raising activities.
Purpose/Rationale
To raise funds for the company through permissible modes.
Capital Structure Impact
Potential future impact on capital structure depending on the chosen fund-raising mode (rights issue, preferential issue, convertible securities, warrants, or other instruments). The specific impact will be determined at a later stage.
Authorization Details
The Board authorized management to:
- Evaluate various fund-raising options
- Appoint intermediaries
- Undertake necessary due diligence
- Negotiate terms and conditions
- Finalize the structure of the proposed fund-raising
- Undertake all necessary actions related to the fund-raising
Future Determinations
The mode of fund-raising, size of the issue, pricing, class of securities, terms and conditions will be determined at the appropriate stage based on:
- Management and advisor recommendations
- Prevailing market conditions
- Applicable statutory and regulatory approvals
- Shareholder approval where required